CN110903397A - 具有降低低密度脂蛋白的pcsk9特异性全人源抗体及其应用 - Google Patents
具有降低低密度脂蛋白的pcsk9特异性全人源抗体及其应用 Download PDFInfo
- Publication number
- CN110903397A CN110903397A CN201911008237.3A CN201911008237A CN110903397A CN 110903397 A CN110903397 A CN 110903397A CN 201911008237 A CN201911008237 A CN 201911008237A CN 110903397 A CN110903397 A CN 110903397A
- Authority
- CN
- China
- Prior art keywords
- antibody
- fully human
- variable region
- chain variable
- human antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911008237.3A CN110903397B (zh) | 2019-10-22 | 2019-10-22 | 具有降低低密度脂蛋白的pcsk9特异性全人源抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911008237.3A CN110903397B (zh) | 2019-10-22 | 2019-10-22 | 具有降低低密度脂蛋白的pcsk9特异性全人源抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110903397A true CN110903397A (zh) | 2020-03-24 |
CN110903397B CN110903397B (zh) | 2022-07-12 |
Family
ID=69814652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911008237.3A Active CN110903397B (zh) | 2019-10-22 | 2019-10-22 | 具有降低低密度脂蛋白的pcsk9特异性全人源抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110903397B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115260309A (zh) * | 2021-04-29 | 2022-11-01 | 青岛大学 | 人源氧化型低密度脂蛋白单链抗体及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037554A (zh) * | 2015-06-12 | 2015-11-11 | 成都贝爱特生物科技有限公司 | 抗人pcsk9抗体的制备及其用途 |
CN106589127A (zh) * | 2015-10-16 | 2017-04-26 | 钜川生物医药 | 一种pcsk9抗体及其制备方法和应用 |
-
2019
- 2019-10-22 CN CN201911008237.3A patent/CN110903397B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105037554A (zh) * | 2015-06-12 | 2015-11-11 | 成都贝爱特生物科技有限公司 | 抗人pcsk9抗体的制备及其用途 |
CN106589127A (zh) * | 2015-10-16 | 2017-04-26 | 钜川生物医药 | 一种pcsk9抗体及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
GOUNI-BERTHOLD I等: "PCSK9 Antibodies for the Treatment of Hypercholesterolemia", 《NUTRIENTS》 * |
ZHANG XL等: "Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials", 《BMC MEDICINE》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115260309A (zh) * | 2021-04-29 | 2022-11-01 | 青岛大学 | 人源氧化型低密度脂蛋白单链抗体及其应用 |
CN115260309B (zh) * | 2021-04-29 | 2024-05-07 | 青岛大学 | 人源氧化型低密度脂蛋白单链抗体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN110903397B (zh) | 2022-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108409860B (zh) | 抗人白细胞介素-4受体α单克隆抗体、其制备方法和应用 | |
JP6006404B2 (ja) | 抗BLyS抗体 | |
WO2019228266A1 (zh) | 抗白细胞介素-17a抗体、其药物组合物及其用途 | |
JP2014518640A (ja) | β−クロトおよびFGF受容体を含む複合体に結合するヒト抗原結合タンパク質 | |
JP2023126929A (ja) | ヒトil4raに対する抗体及びその使用 | |
JP6731933B2 (ja) | Pcsk9抗体、及び医薬組成物とその使用 | |
KR20220119394A (ko) | Tslp-관련 질환에 대한 치료제의 개발 및 적용 | |
US8128932B2 (en) | Anti-VEGFR monoclonal antibody, method of making and uses thereof | |
CN110903397B (zh) | 具有降低低密度脂蛋白的pcsk9特异性全人源抗体及其应用 | |
RU2758092C1 (ru) | АНТИТЕЛО К IL-4Rα И ЕГО ПРИМЕНЕНИЕ | |
WO2015006554A1 (en) | Therapeutic antibodies and uses thereof | |
KR102231685B1 (ko) | 인간 항-il-32 항체 | |
US20240084019A1 (en) | Anti-Chemokin Like Receptor 1 Humanized Antibodies and Their Therapeutic Applications | |
WO2015113494A1 (zh) | 双功能融合蛋白及其制备方法和用途 | |
AU2021422014A1 (en) | Cell strain for producing biosimilar drug of ustekinumab and production method therefor | |
WO2022174781A1 (zh) | 多结构域融合蛋白及其应用 | |
KR101854529B1 (ko) | 인간 및 마우스 Sema3A에 교차결합하는 항체 및 그의 용도 | |
KR20130126543A (ko) | 항 il-6r 및 tnfr2을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 자가 면역 질환 치료용 약학 조성물 | |
CN114380906B (zh) | 一种抗il-17a的单域抗体及其用途 | |
RU2807060C1 (ru) | Антитело к альфа-рецептору интерлейкина-4 человека, способ его получения и его применение | |
WO2024041477A1 (zh) | 多结构域融合蛋白的用途 | |
WO2023142109A1 (zh) | 一种长效重组人生长激素及其应用 | |
WO2021093753A1 (zh) | 一种能够与人4-1bb结合的分子及其应用 | |
WO2023134742A1 (zh) | 一种三靶点抗肿瘤药物、其制备方法及其应用 | |
WO2024093652A1 (en) | APPLICATION OF NANOBODY TARGETING ON IL-6Rα |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220130 Address after: 132013 No.5 Jilin Street, Jilin City, Jilin Province Applicant after: JINLIN MEDICAL University Address before: 132013 No.5 Jilin Street, Jilin City, Jilin Province Applicant before: JINLIN MEDICAL University Applicant before: CHONGQING BIOMEAN TECHNOLOGY CO.,LTD. |
|
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Huiyan Inventor after: Cai Jianhui Inventor after: Yin Moli Inventor after: Tang Lu Inventor after: Meng Fanwei Inventor after: Xu Song Inventor after: Hu Chuanmin Inventor before: Cai Jianhui Inventor before: Xu Song Inventor before: Wang Huiyan Inventor before: Meng Fanwei Inventor before: Yin Moli Inventor before: Hu Chuanmin Inventor before: Tang Lu |
|
GR01 | Patent grant | ||
GR01 | Patent grant |